{"entity":{"id":"andrew-zhu","kind":"person","name":"Andrew X. Zhu","aka":[],"tldr":"Oncologist who led REACH-2, the first positive biomarker-selected trial in liver cancer, which established ramucirumab for patients with a high alpha-fetoprotein level.","summary":"Andrew Zhu led the liver cancer programme at Massachusetts General Hospital for many years. He was first author of the 2019 Lancet Oncology report of REACH-2, which showed that ramucirumab lengthened survival compared with placebo in previously treated hepatocellular carcinoma with alpha-fetoprotein of 400 ng/mL or more, the first positive phase 3 trial in liver cancer to select patients by a biomarker. He has also led trials of ivosidenib in IDH1-mutant cholangiocarcinoma.","asOf":"2026-09-18","links":[],"tags":["hcc","biliary","trialist"],"related":[],"cancers":["hcc-advanced","hcc","intrahepatic-cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["reach-2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Hepatobiliary medical oncologist and trial lead","specialisms":["Hepatocellular carcinoma","Biliary tract cancer","Biomarker-selected trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhu%5BAuthor%5D"}],"papers":[]},"route":"/people/andrew-zhu/","neighbours":{"cancer":[{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/"}],"trial":[{"id":"reach-2","kind":"trial","name":"REACH-2","route":"/trials/reach-2/"}]}}